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Abstract
Background:  We sought to assess injection practices, means of acquiring and disposing of
syringes, and utilization and knowledge of harm reduction resources among injection drug users
(IDUs) entering methadone maintenance treatment (MMT).
Methods: Interviews with 100 consecutive patients, including 35 IDUs, entering a MMT program
in the Bronx, NY.
Results: Utilization of unsafe syringe sources was reported by 69% of IDUs in our sample. Most
(80%) IDUs reused syringes, and syringe sharing was also common. Fewer than half knew that non-
prescription pharmacy purchase of syringes was possible. The most common means of disposing
of injecting equipment were the trash (63%) and syringe exchange programs (49%).
Conclusions: These findings indicate that drug users entering treatment under-utilize sanctioned
venues to obtain sterile syringes or safely dispose of used injection equipment. Programs providing
services to drug users should adopt a proactive stance to address the safety and health issues faced
by injectors.
Introduction
The need for injection drug users (IDUs) to have access to
sterile syringes for the prevention of blood-borne disease
and other health problems is well established [1]. Injec-
tion drug use accounts for approximately one-third of all
AIDS cases in the United States, and for 60% of new hep-
atitis C infections [2]. The Institute of Medicine of the
National Academy of Sciences has stated that " [f]or injec-
tion drug users who cannot or will not stop injecting
drugs, the once-only use of sterile needles and syringes
remains the safest, most effective approach for limiting
HIV transmission" [3]. Nonetheless, IDUs' access to sterile
syringes is generally inadequate to limit their risk of
acquiring and transmitting infections [4-6]
Syringe exchange is associated with reduced HIV transmis-
sion among IDUs [7,8], yet existing syringe exchange pro-
grams (SEPs) are able to meet only a fraction of injectors'
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need for sterile injection equipment [4]. To increase access
to sterile syringes, New York State enacted the Expanded
Syringe Access Program (ESAP) in 2001, which legalized
pharmacy sale of syringes to adults without a prescription.
This program provides a means for drug treatment and
other health care providers to promote safer injecting
practices to their drug using patients without providing
syringes on-site. Yet ESAP, while a significant step for-
ward, has been utilized only modestly, due in part to a
ban on advertising and to slow uptake by service providers
working with drug users [9].
Methadone maintenance treatment (MMT), because of its
effectiveness in treating heroin dependence, is also associ-
ated with reduced risk for acquiring or transmitting HIV
infection [10-12]. Yet while the majority of patients
receiving methadone maintenance treatment cease using
heroin, some continue to inject, particularly in the early
months of treatment [13]. Others inject cocaine, a behav-
ior that methadone influences minimally if at all [14,15].
Education about safer drug use ("harm reduction") and
related interventions, including provision of sterile
syringes, have not been accepted practice at most metha-
done maintenance treatment programs (MMTPs) in the
United States. This reflects, in part, the highly regulated
model of MMT that evolved in the United States well
before the age of HIV/AIDS, as well as the strong focus on
abstinence of many MMTPs [16,17]. The notion of offer-
ing methadone treatment along with access to sterile
syringes seems discordant, or even contradictory, to many
MMT staff. Finally, some MMT providers are concerned
that acknowledgment of ongoing drug use among their
patients might damage already shaky community and
public relations. Together, these obstacles have hindered
MMTPs from endorsing harm reduction interventions
such as access to sterile injection equipment.
To determine the need and acceptability for an interven-
tion at a MMT to facilitate sterile syringe access and safe
disposal, we surveyed patients newly enrolled in metha-
done maintenance treatment to define their injecting
behaviors and to assess their access to sterile syringes and
their syringe disposal practices.
Methods
This study was conducted at a single MMTP in the Bronx,
NY, which serves as the intake site for a network of 8 addi-
tional MMTPs. Patients undergo comprehensive medical
and psychosocial assessment and methadone induction,
typically receiving care at this clinic for six months and
attaining a stable methadone dose before being trans-
ferred to another site in the system for ongoing mainte-
nance treatment. The average census of the intake clinic is
500 patients.
A 24-item survey was administered to all consecutive new
entrants to the MMTP over a 3-month period in 2002–
2003, beginning 22 months after ESAP's implementation.
Study eligibility criteria specified that, in addition to
meeting the program's entry criteria (≥18 years old; ≥1
year of opioid dependence; and at least one prior attempt
at treatment or detoxification), participants must have
been in treatment for more than 2 weeks and less than 2
months. To ensure that all study participants were just
beginning methadone treatment, patients were excluded
if they had transferred directly from another MMTP with-
out a lapse in methadone treatment.
Patients were approached in the waiting area and asked to
participate in the survey. Participation was voluntary, and
no compensation was offered. The survey was adminis-
tered in English or Spanish by one of us (JM), who read
the questions and recorded patient responses. All infor-
mation was self-reported. None of the responses were
shared with the MMTP staff, and the interviewer was not
part of the treatment team. Verbal informed consent was
obtained from all participants, and the study was
approved by the institutional review board of the Albert
Einstein College of Medicine.
The survey included questions about injection history,
sources of syringes, knowledge of and experiences with
the ESAP program, methods of disposing of used injecting
equipment, and self-reported viral hepatitis and HIV
infection status. Subjects were asked to name all places at
which they obtained syringes in the past 6 months, to
specify their primary source of syringes, and to identify all
methods used to dispose of used syringes in the past year.
Participants' opinions as to whether MMTPs should dis-
tribute syringes or have sharps containers on-site were
also solicited.
Patients who reported injecting drugs during the prior six
months were designated "current IDUs" and were selected
for analysis. Needle or syringe exchange programs, phar-
macies, and medical providers were classified as "safe"
sources of syringes. Street sellers, acquaintances (friend,
relative, partner, spouse), shooting galleries, or needles
found on the street were considered "unsafe" sources,
since the sterility of syringes obtained from these sources
is not assured. Frequency analyses were performed using
SPSS (SPSS for Windows, Chicago, IL, 1999).
Results
Of 108 patients meeting eligibility criteria, 4 (4%) left the
program before being interviewed, and 4 (4%) declined to
participate. Of the remaining 100 participants, 35 were
current IDUs, and are the subject of this analysis.Harm Reduction Journal 2006, 3:8 http://www.harmreductionjournal.com/content/3/1/8
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Study participants had a mean age of 38 years (range 19–
61), and the majority was male (Table 1). Seventy-four
percent were Hispanic and 14% African American. Self-
reported prevalence of HIV infection was 31%, and hepa-
titis C infection was reported by 69%. The majority of sub-
jects (94%) were interviewed during the 3rd or 4th week
of their participation in methadone treatment. Five inter-
views (14%) were administered in Spanish.
Among participants reporting injecting during the previ-
ous six months, 51% (n = 18) had injected in the past
week, and an additional 29% (n = 10) had injected in the
past month, despite being enrolled in methadone treat-
ment for the past several weeks. An additional 23 partici-
pants (from the original sample of 100) had a history of
injection drug use, but had not injected in the past six
months.
Current IDUs' sources of syringes during the prior 6
months are presented in Table 2. Though half (53%) used
a primary syringe source that was "safe," utilization of
unsafe sources was common. The majority (69%) of IDUs
reported some utilization of unsafe sources, predomi-
nantly street sellers (including drug dealers and needle
sellers). Friends, relatives, spouses, and partners were also
commonly cited sources. Syringe exchange programs were
heavily utilized, with 46% of participants reporting
obtaining syringes from an exchange, and 40% citing
exchanges as their primary syringe source. Pharmacies
were a primary syringe source for only 11% (n = 4), but
were utilized at least occasionally by an additional 20% (n
= 7). During the past six months, 2 subjects reported hav-
ing visited a shooting gallery, and 1 had used a syringe
found on the street. None of these current IDUs had
received syringes from a health care provider.
Measures of syringe access and availability are shown in
Table 3. Most (80%) subjects stated that they typically
reused syringes, and syringe sharing was common. Only
46% of these current IDUs knew that it was possible to
buy syringes at a pharmacy without a prescription, and
43% (n = 15) had attempted to do so. Among those who
tried buying syringes in a pharmacy, half reported having
been refused sale on at least one occasion.
More than half (54%) of participants paid for syringes, at
prices ranging up to two dollars for a single syringe. Those
who reported pharmacies as their primary source of
syringes paid less than one dollar per syringe (modal price
less than $0.50), while those who bought syringes prima-
rily from street sellers paid fifty cents to two dollars per
syringe (modal price $2.00). Of those who named syringe
exchange programs as their primary source of syringes,
38% (n = 5) typically traveled more than 20 minutes (or
>10 blocks) to get syringes. No subject who named either
pharmacies or street sellers as their primary source of
syringes traveled this far.
Means of disposal of used syringes are shown in Figure 1.
By far the most common disposal site was the regular
trash. Most participants reported breaking the syringe tip
before discarding, and 32% of those disposing in the trash
reported placing their syringes in a container before
throwing them away. The second most common means of
disposal was the sharps container at a syringe exchange
program, utilized by 49% of participants.
Discussion
Recent enrollees to MMT who continue to inject drugs
often utilize unsafe means of obtaining and disposing of
syringes. Though MMT is effective at reducing and elimi-
nating heroin use, some patients continue to inject illicit
drugs during treatment [13-15]. Because of their emphasis
on eliminating drug use, MMTPs traditionally have not
Table 2: Sources of syringes in the past 6 months (n = 35)
Source Utilized 
No. (%)
Primary source
No. (%)
Safe Sources 22 (62.9) 18 (52.9)
Syringe exchange program 19 (45.7) 14 (40.0)
Pharmacy 11 (31.4) 4 (11.4)
Unsafe Sources 24 (68.6) 16 (47.0)
Purchased on street 18 (51.4) 8 (22.9)
Friends/relatives 15 (42.9) 7 (20.0)
Spouse/partner 10 (28.6) 1 (2.9)
Shooting gallery 2 (5.7) 0
Found 1 (2.9) 0
Table 1: Patient Demographics: Recent MMTP entrants who 
injected drugs in the past 6 months
Characteristic Participants (n = 35)
No.(%)
Age,
mean (range) 38 (19–61)
Sex
Men 19 (54.3)
Ethnicity
Hispanic 26 (74.3)
African American 5 (14.3)
Caucasian 4 (11.4)
HIV positive* 11 (31.4)
HCV positive* 24 (68.6)
Time in treatment
2–4 weeks 33 (94.3)
5–8 weeks 2 (0.6)
Recent injection drug use
Injected in past week 18 (51.4%)
Injected in past month 28 (80.0%)
*Self-reportedHarm Reduction Journal 2006, 3:8 http://www.harmreductionjournal.com/content/3/1/8
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focused on harm reduction, nor explicitly supported safer
injection practices among patients who continue to inject.
Yet elimination of drug use is not an immediately attain-
able goal for many patients, whose risk of acquiring and
transmitting infections and of other injection-related
harm persists despite participation in drug treatment. Our
data make clear the need for increased attention to safer
injecting practices for IDUs recently enrolled in MMTP,
and suggest that treatment programs should play a more
proactive role in promoting safe syringe use and disposal.
Our data suggest that even for IDUs residing in an urban
setting rich in syringe exchange programs, with over 100
pharmacies registered to sell syringes, access to safe
syringes and proper disposal is inadequate. Forty percent
(40%) of IDUs reported sharing syringes in the past 6
months, and only one in five was able to use a new syringe
for each injection. Though very high-risk sources such as
shooting galleries and found syringes were avoided by
most participants, even low-level use of such sources is
highly problematic, given the considerable risk of disease
transmission. The rate of syringe sharing in our sample is
similar to that reported in a study of IDUs in New York
City in 1996–1997, which documented "receptive" and
"distributive" sharing rates of 24% and 19%, respectively
[18]. Though substantial geographic and temporal varia-
tion exists in drug injectors' access to SEPs and other
sources of sterile injection equipment in the United States
[19-26], our data are consistent with the findings of inves-
tigators in a range of locations that efforts to ensure ade-
quate community-level access are generally insufficient to
meet the demand [3-6].
Over-the-counter syringe purchase in pharmacies (the
ESAP program) has been an important initiative to
increase access to safe injection equipment for injectors in
New York State. The fact that many of the injectors in our
Location of syringe disposal (n = 35) Figure 1
Location of syringe disposal (n = 35).
Table 3: Measures of syringe access and availability
Question Participants (n = 35)
No. (%)
How many times do you usually use a syringe?
1 7 (20.0)
2–5 23 (65.7)
>5 5 (14.3)
Have you shared syringes in the past 6 months?
Yes 14 (40.0)
No 21 (60.0)
How much do you usually pay for a syringe?
$0 16 (45.7)
< $1 7 (20.0)
$1 4 (11.4)
$2 8 (22.8)
Have you ever used a needle exchange program?
Yes 22 (62.9)
No 13 (37.1)
Are you aware of ESAP, or do you know that adults can buy syringes in the pharmacy without a 
prescription?
Yes 16 (45.7)
No 19 (54.3)
Have you tried to purchase syringes in pharmacy since January 2001?
Yes 15 (42.9)
No 20 (57.1)
Have you tried to buy syringes in a pharmacy and been refused since January 2001?
Yes 7 (50.0% of those attempting purchase)
No 7 (50.0% of those attempting purchase)Harm Reduction Journal 2006, 3:8 http://www.harmreductionjournal.com/content/3/1/8
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sample had used pharmacies to buy syringes is testimony
to the success of the ESAP program. Further work remains,
however, to optimize its impact. Though ESAP was imple-
mented almost two years prior to our interviews, most
IDUs were not aware of its essential benefit; that they
could purchase syringes at pharmacies without a prescrip-
tion. Utilization rates in our treatment population are not
dissimilar from those reported among IDUs in Harlem
and the South Bronx, according to an independent evalu-
ation of the ESAP program [9]. This evaluation also sug-
gested that African American and Hispanic IDUs (the
majority of our study population) are much less likely to
report pharmacy purchase. Significantly greater commu-
nity outreach regarding the ESAP program is clearly indi-
cated.
Pharmacy refusal to sell syringes was commonly experi-
enced by study participants. While 43% of our partici-
pants had attempted to purchase syringes at a pharmacy
since the implementation of ESAP, only 31% reported
succeeding. Refusals to sell syringes were documented in
the first year of ESAP by Finkelstein et al., who found that
31% of New York City pharmacists and 67% of those in
the Bronx declined to sell syringes despite being registered
ESAP providers [27].
Syringe exchange programs were a major source of
syringes for our participants, but IDUs who relied on
them as the primary source of syringes reported traveling
much farther to get syringes than those who used other
sources. SEPs also have limited hours for syringe
exchange, which may be an additional hardship, relative
to pharmacy sale, for some users. Participants who uti-
lized syringe exchange programs were more likely to use
them as their primary source of syringes, while pharmacy
purchasers were more likely to use the pharmacy as a sec-
ondary or supplemental source. This might reflect the fact
that syringes are free at syringe exchange programs, and
that IDUs are taking advantage of the other services
(meals, caseworkers, support groups, acupuncture, etc.)
offered at SEPs. It may also be that IDUs have other rea-
sons to feel less comfortable purchasing syringes in a
pharmacy, including reluctance to reveal themselves as
drug users, fear of discrimination, and concerns regarding
stigmatization or refusal of sale by the pharmacist.
Our finding that regular trash is the most commonly cited
syringe disposal site points starkly to the need for
improved systems for safe syringe disposal. Disincentives
for IDUs to carry syringes to a safer disposal location
include fear of arrest or harassment by the police, and of
being identified as a drug user [28,29]. Yet nearly half of
current IDUs reported disposing of syringes at a syringe
exchange program at least once in the past year, suggesting
that innovative strategies for community-based disposal
may have positive results.
Our study has several limitations. The size of our sample
of current IDUs was modest. The proportion of IDUs in
our sample of consecutive treatment entrants is consistent
with current trends in New York City [30]. We sampled
participants at a single South Bronx MMTP. However,
since this research site is the intake program for a large
network of methadone programs, it draws patients from
throughout the Bronx and, to a lesser extent, other areas
of New York City. This MMTP thus has a high proportion
of patients in their first months of methadone treatment,
a subgroup for whom our findings are especially applica-
ble. Selection bias was minimized by enrolling consecu-
tive patients and by the high response rate. Although we
used self-report data, and thus may have underestimated
the prevalence of disease and of injecting and other risky
behaviors, other studies of IDUs have demonstrated good
reliability using similar questions [31,32].
Our findings suggest that drug treatment programs serving
injectors should more actively address the safety and
health issues associated with injection drug use. Thought-
ful education of patients, staff and communities may be
needed to help drug treatment and harm reduction pro-
viders recognize their common ground. As a significant
number of patients continue to inject during the early
phase of methadone maintenance treatment, injectors
receiving services in this setting should not be excluded
from complementary efforts to minimize injection-
related harm.
To address these issues successfully, drug treatment pro-
grams might offer education, sterile syringe access, and
syringe disposal through a combination of on-site services
and referral to community-based providers. By legalizing
pharmacy purchase of syringes, ESAP and similar pro-
grams provide an opportunity for providers of drug treat-
ment and health care services to promote health-
protecting behaviors to patients who continue to inject.
Innovative strategies to enhance access to sterile syringes
and foster safe syringe disposal for MMTP participants
who continue to inject merit vigorous exploration.
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